Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $177

Benzinga Newsdesk www.benzinga.com Positive 74.8%

Neg 0% Neu 0% Pos 74.8%

Wells Fargo analyst Benjamin Burnett maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $175 to $177.